SynteractHCR Expands Senior Management Team with Appointment of Etienne Drouet as Vice President, Strategic Development
SynteractHCR, a full-service, international contract research organization (CRO), has hired Etienne Drouet as vice president, strategic development.
SAN DIEGO – Feb. 26, 2015 –SynteractHCR, a full-service, international contract research organization (CRO), has hired Etienne Drouet as vice president, strategic development. This is a new position created to augment the depth of the company’s oncology and complex trial expertise. Adding experience to an already capable senior management team brings new perspectives and enhances the team’s skills as this global CRO continues its focus on the small and mid-size biopharma segment.
Etienne Drouet has more than 20 years of experience in executive leadership, program and project management, clinical trial management, and research and development within the contract research and biopharmaceutical industries. At SynteractHCR he will join the senior management team, helping to develop company strategy and business models. His primary objective will be to ensure excellence in operational delivery to clients. He will report directly to CEO Wendel Barr.
“Since we work with smaller and mid-sized companies on complex global trials, integrating his extensive drug development knowledge is key to further improving both the strategic thinking and executional support our clients request,” said Wendel Barr, CEO of SynteractHCR. “We are delighted to have him on board the team.”
Mr. Drouet joins SynteractHCR from Premier Research where he was executive director, global oncology. Previously he was a program manager and senior project manager at ICON; held project management positions at AAI Pharma, and Cvitkovic and Associés Consultants; was a senior CRA at the Breast Cancer International Research Group; and a research scientist with Sanofi Aventis. Drouet has notable therapeutic experience in solid tumor and hematological cancers as well as CNS (central nervous systems).
He has an engineering degree in Biotechnology from the European School of Biotechnology in Strasbourg. Etienne Drouet also holds a Master in Science with a major in Cell Biology, Molecular Genetics, and Virology from the University Louis Pasteur in Strasbourg, Alsace, France.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
